Harel Insurance Reports 6.0% Passive Stake in Teva Pharmaceutical Industries

Overview

On November 2, 2026, Harel Insurance Investments & Financial Services Ltd. filed Amendment No. 2 to Schedule 13G for Teva Pharmaceutical Industries Ltd. (CIK: 0000818686), reporting beneficial ownership of 70,418,201 Ordinary Shares, representing 6.0% of the company's outstanding shares as of September 30, 2026.

Ownership Breakdown

According to Item 4 of the filing:

• 68,375,069 shares are held for public clients via provident, mutual, and pension funds, insurance policies, and ETFs managed by independently operated subsidiaries.
• 1,027,935 shares are held in third-party client accounts managed as portfolio managers without voting rights.
• 1,015,197 shares are held directly for Harel's own account.
• Shared Voting Power: 69,390,266 shares
• Shared Dispositive Power: 70,418,201 shares
• Sole Voting / Dispositive Power: 0 shares

Market & Trading Significance

The filing is a standard passive Schedule 13G amendment pursuant to Rule 13d-1(c). Because the vast majority of shares are managed on behalf of institutional and retail public funds with independent investment management, and Harel disclaims beneficial ownership beyond its own account of 1,015,197 shares, this disclosure reflects routine institutional portfolio management rather than activist or directional intent.